PDCD1 and melanoma: Moreover, studies have shown that increased IL-17 signaling and elevated serum IL-17 levels are positively correlated with better therapeutic responses in melanoma patients treated with dual cytotoxic T-lymphocyte antigen 4 and PD-1 immune checkpoint inhibitors, and are linked to prolonged overall survival for these patients (54).